How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries

Applied Health Economics and Health Policy

Volumn 15, Issue 3, 2017, Pages 307-321

  Vogler, Sabine ^a   Paris, Valérie ^b   Ferrario, Alessandra ^c   Wirtz, Veronika J ^d   de Joncheere, Kees ^e   Schneider, Peter ^a   Pedersen, Hanne Bak ^f   Dedet, Guillaume ^f   Babar, Zaheer Ud Din ^g  

^a GESUNDHEIT ÖSTERREICH GMBH   (Austria)

^b OECD   (France)

^c LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e WORLD HEALTH ORGANIZATION   (Switzerland)

^f WHO REGIONAL OFFICE FOR EUROPE   (Denmark)

^g UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT;

BIOMEDICAL TECHNOLOGY ASSESSMENT; COST EFFECTIVENESS ANALYSIS; DRUG INDUSTRY; DRUG SURVEILLANCE PROGRAM; EUROPEAN; FUNDING; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH CARE SYSTEM; HUMAN; MEDICINE; PROSPECTIVE PRICING; REIMBURSEMENT; REVIEW; VALUE-BASED INSURANCE DESIGN; COST; DRUG COST; ECONOMICS; EUROPE; HEALTH CARE DELIVERY; PHARMACOECONOMICS; STATISTICS AND NUMERICAL DATA;

COSTS AND COST ANALYSIS; DRUG COSTS; ECONOMICS, PHARMACEUTICAL; EUROPE; HEALTH POLICY; HEALTH SERVICES ACCESSIBILITY; HUMANS; INSURANCE, HEALTH, REIMBURSEMENT;

EID: 85008481918     PISSN: 11755652     EISSN: 11791896     Source Type: Journal    
DOI: 10.1007/s40258-016-0300-z     Document Type: Review

References (156)

1. European Commission. Council conclusions on innovation for the benefit of patients (2014/C 438/06). Brussels: 6 December 2014.
2. Council of the European Union. Council conclusions on the “Reflection process on modern, responsive and sustainable health systems”. Employment, Social Policy, Health and Consumers Affairs. Council meeting. Brussels, 10 December 2013. 2013.
3. WHO Regional Office for Europe. Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. Copenhagen: 2015.
4. Ministry of Health Welfare and Sport. Summary of Medicines Plan. The Hague: 2016. Accessible at: http://english.eu2016.nl/binaries/eu2016-en/documents/publications/2016/03/1/summary-of-medicins/summary-of-medicines-plan.pdf. Accessed 14 May 2016.
5. Iyengar S, Tay-Teo K, Vogler S, Beyer P, Wiktor S, de Joncheere K, et al. Prices, costs, and affordability of new medicines for hepatitis C in 30 countries: an economic analysis. PLoS Med. 2016;13(5):e1002032.
6. Howard DH, Bach PB, Berndt ER, Conti RM. Pricing in the market for anticancer drugs. National Bureau of Economic Research. Nashville: American Economic Association; 2015.
7. Tefferi A, Kantarjian H, Rajkumar SV, Baker LH, Abkowitz JL, Adamson JW, et al. In support of a patient-driven initiative and petition to lower the high price of cancer drugs. Mayo Clin Proc. 2015;90(8):996–1000.
8. Light DW, Kantarjian H. Market spiral pricing of cancer drugs. Cancer. 2013;119(22):3900–2.
9. Paris V, Hewlett E, Auraaen A, Alexa J, Simon L. Health care coverage in OECD countries in 2012. Paris: OECD Working Paper No. 88, OECD Publishing, 2016.
10. OECD. OECD Health Statistics 2016. Paris: Organisation for Economic Co-operation and Development; released 30 June 2016.
11. Bouvy J, Vogler S. Background Paper 8.3 Pricing and Reimbursement Policies: Impacts on Innovation. In: World Health Organization, editor. Priority Medicines for Europe and the World “A Public Health Approach to Innovation” Update on 2004 Background Paper. Geneva 2013.
12. EFPIA. Patients’ W.A.I.T. Indicator—Report 2011. 2011. http://www.efpia.eu/uploads/Patients_WAIT_Report_2011_FINAL_070811_1.doc. Accessed 23 June 2016.
13. Heads of Medicines Agencies. Report of Task Force of HMA. Availability of Human Medicinal Products. Madeira: 2007.
14. Leopold C, Rovira J, Habl C. Generics in small markets or for low volume medicines European Union. Vienna: EMINet, 2010.
15. Vogler S, Kilpatrick K, Babar Z-U-D. Analysis of medicine prices in New Zealand and 16 European Countries. Value Health. 2015;18(4):484–92.
16. Vogler S, Vitry A, Babar Z-U-D. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
17. Kanavos P, Ferrario A, Vandoros S, Anderson GF. Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs. Health Aff. 2013;32(4):753–61.
18. Kanavos P, Vandoros S, Irwin R, Nicod E, Casson M. Differences in costs of and access to pharmaceutical products in the EU. Brussels: European Parliament; 2011.
19. Danzon PM, Furukawa MF. International prices and availability of pharmaceuticals in 2005. Health Aff. 2008;27(1):221–33.
20. Leopold C, Mantel-Teeuwisse AK, Vogler S, de Joncheere K, Laing RO, Leufkens HGM. Is Europe still heading to a common price level for on-patent medicines? An exploratory study among 15 Western European countries. Health Policy. 2013;112:209–16.
21. Brekke KR, Holmås TH, Straume OR. Are Pharmaceuticals Still Inexpensive in Norway? A Comparison of Prescription Drug Prices in Ten European Countries. SNF Report No. 08/10. 2010.
22. Simoens S. International comparison of generic medicine prices. Curr Med Res Opin. 2007;23(11):2647–54.
23. Jönsson B, Hofmarcher T, Lindgren P, Wilking N. Comparator report on patient access to cancer medicines in Europe revisited. IHE Rep. 2016;4:228.
24. Jönsson B, Persson U, Wilking N. Innovative Treatments for cancer in Europe—value, cost, and access. Lund: IHE-Report; 2016.
25. Nolte E, Corbett J. International variation in drug usage—an exploratory analysis of the “causes” of variation. London: RAND Europe; 2014.
26. Nolte E, Newbould J, Conklin A. International variation in the usage of medicines—a review of literature. London: RAND Europe; 2010.
27. Ferech M, Coenen S, Malhotra-Kumar S, Dvorakova K, Hendrickx E, Suetens C, et al. European Surveillance of Antimicrobial Consumption (ESAC): outpatient antibiotic use in Europe. J Antimicrob Chemother. 2006;58(2):401–7.
28. Hoebert J, Laing R, Stephens P. Pharmaceutical consumption. The world medicines situation 2011. Geneva: World Health Organisation; 2011.
29. Hoebert JM. Cross-country variation in medicines use; a pharmaceutical system perspective; 2013.
30. Hoebert JM, Souverein PC, Mantel-Teeuwisse AK, Leufkens HG, van Dijk L. Reimbursement restriction and moderate decrease in benzodiazepine use in general practice. The Annals of Family Medicine. 2012;10(1):42–9.
31. Penchansky R, Thomas JW. The concept of access: definition and relationship to consumer satisfaction. Med Care. 1981;19(2):127–40.
32. World Health Organization. Equitable access to essential medicines: a framework for collective action. 2004.
33. Management Sciences for Health. Defining and Measuring Access to Essential Drugs, Vaccines, and Health Commodities. Report of the WHO-MSH Consultative Meeting, Ferney-Voltaire, France, December 11–13, 2000 Geneva: World Health Organization. 1999. http://projects.msh.org/seam/reports/measuring_access_Dec2000.pdf. Accessed 3 June 2016.
34. Bigdeli M, Jacobs B, Tomson G, Laing R, Ghaffar A, Dujardin B, et al. Access to medicines from a health system perspective. Health policy and planning. 2012.
35. United Nations. Sustainable Developmet Goals, [28 July 2016]. https://sustainabledevelopment.un.org/. Accessed 28 June 2016.
36. World Health Organization. Essential medicines and health products. Monitoring and Evaluation 2016. http://www.who.int/medicines/areas/policy/monitoring/en/. Accessed 1 Nov 2016.
37. World Health Organization. Global Reference List of 100 Core Health Indicators. Luxembourg: World Health Organization; 2015.
38. Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Brussels: European Commission, Directorate-General for Economics and Financial Afairs; 2012.
39. Paris V, Belloni A. Value in Pharmaceutical Pricing. OECD Health Working Papers, No. 63. Paris: OECD Publishing, 2013.
40. Drummond M, Jönsson B, Rutten F, Stargardt T. Reimbursement of pharmaceuticals: reference pricing versus health technology assessment. Eur J Health Econ. 2011;12(3):263–71.
41. World Health Organization. WHO guideline on country pharmaceutical pricing policies. Geneva: World Health Organization; 2013.
42. Zimmermann N, Vogler S, Bak Pedersen H. Policy options to deal with high-cost medicines—survey with European policy-makers. J Pharm Policy Pract. 2015;8(Suppl 1):P8.
43. Vogler S, Lepuschütz L, Schneider P, Stühlinger V. Study on enhanced cross-country coordination in the area of pharmaceutical product pricing. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH; 2016.
44. OECD. Pharmaceutical Pricing Policies in a Global Market. Paris: OECD, 2008.
45. Stargardt DVT, Schreyögg J. Impact of cross-reference pricing on pharmaceutical prices. Appl Health Econ Health Policy. 2006;5(4):235–47.
46. Danzon PM, Towse A. Differential pricing for pharmaceuticals: reconciling access, R&D and patents. Int J Health Care Finance Econ. 2003;3(3):183–205.
47. Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99.
48. Espin J, Rovira J, de Labry AO. Working paper 1: External price referencing—review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International, 2011.
49. Rémuzat C, Urbinati D, Mzoughi O, El Hammi E, Belgaied W, Toumi M. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3:1–11.
50. Europe Economics. External price referencing. London: Europe Economics; 2013.
51. Michel M, Toumi M. Access to orphan drugs in Europe: current and future issues. Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(1):23–9.
52. Persson U, Jönsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016;14(1):1–8.
53. Kanavos P, Nicod E, Espin J. Short-and long-term effects of value-based pricing vs. external price referencing. 2010.
54. Danzon PM, Wang YR, Wang L. The impact of price regulation on the launch delay of new drugs—evidence from twenty-five major markets in the 1990s. Health Econ. 2005;14(3):269–92.
55. Ferrario A, Reinap M, Pedersen HB, Kanavos P. Availability of medicines in Estonia: an analysis of existing barriers and options to address them. Copenhagen: WHO, Regional Office for Europe; 2016.
56. Toumi M, Rémuzat C, Vataire A-L, Urbinati D. External reference pricing of medicinal products: simulation-based considerations for cross-country coordination. Final Report. European Commission, 2014.
57. Glynn D. The effects of parallel trade on affordable access to medicines. Eurohealth. 2009;15(2):1–4.
58. Merkur S, Mossialos E. A pricing policy towards the sourcing of cheaper drugs in Cyprus. Health Policy. 2007;81(2):368–75.
59. Windmeijer F, De Laat E, Douven R, Mot E. Pharmaceutical promotion and GP prescription behaviour. Health Econ. 2006;15(1):5–18.
60. Leopold C, Mantel-Teeuwisse AK, Seyfang L, Vogler S, de Joncheere K, Laing RO, et al. Impact of external price referencing on medicine prices—a price comparison among 14 European countries. South Med Rev. 2012;5(1):34–41.
61. Håkonsen H, Horn AM, Toverud E-L. Price control as a strategy for pharmaceutical cost containment—What has been achieved in Norway in the period 1994–2004? Health policy. 2009;90(2):277–85.
62. Towse A, Pistollato M, Mestre-Ferrandiz J, Khan Z, Kaura S, Garrison L. european union pharmaceutical markets: a case for differential pricing? Int J Econ Bus. 2015;22(2):263–75.
63. Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Review. 2012;5(1):38–46.
64. Claxton K. Oft, Vbp: qed? Health Econ. 2007;16(6):545–58.
65. Godman B, Gustafsson LL. A new reimbursement system for innovative pharmaceuticals combining value-based and free market pricing. Appl Health Econ Health Policy. 2013;11(1):79.
66. Process on Corporate Social Responsibility in the Field of Pharmaceuticals, Platform on Access to Medicines in Europe, Working Group on Mechanism of Coordinated Access to Orphan Medicinal Products (MoCA-OMP). Transparent Value Framework. 2013.
67. Kaplan W, Laing R. Priority Medicines for Europe and the World. Geneva: World Health Organization; 2004.
68. Franken M, le Polain M, Cleemput I, Koopmanschap M. Similarities and differences between five European drug reimbursement systems. Int J Technol Assess Health Care. 2012;28(4):349.
69. Consultative Expert Working Group on Research and Developmen. Follow-up of the report of the Consultative Expert Working Group on Research and Development: Financing and Coordination (CEWG) 2016. http://www.who.int/phi/cewg/en/. Accessed 26 June 2016.
70. Vogler S, Zimmermann N, Habimana K. Study of the policy mix for the reimbursement of medicinal products. Proposal for a best practice-based approach based on stakeholder assessment. Vienna: Commissioned by the European Commission, 2014.
71. Hughes DA. Value-based pricing. Incentive for innovation or zero net benefit? Pharmacoeconomics. 2011;29(9):731–5.
72. Ferrario A, Kanavos P. Managed entry agreements for pharmaceuticals: the European experience. EMINet, 2013.
73. Adamski J, Godman B, Ofierska-Sujkowska G, Osinska B, Herholz H, Wendykowska K, et al. Risk sharing arrangements for pharmaceuticals: potential considerations and recommendations for European payers. BMC Health Serv Res. 2010;10:153.
74. Morel T, Arickx F, Befrits G, Siviero P, van der Meijden C, Xoxi E, et al. Managed entry agreements and orphan drugs: a European comparative study (2006–2012). Value Health. 2013;16(7):A391–A.
75. Garrison LP, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, et al. Performance-based risk-sharing arrangements—good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013;16(5):703–19.
76. Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff. 2011;30(12):2329–37.
77. Iskrov G, Stefanov R. Prospects of risk-sharing agreements for innovative therapies in a context of deficit spending in Bulgaria. Front Public Health. 2015;3:1–4.
78. Ferrario A, Kanavos P. Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Soc Sci Med. 2015;124(1):39–47.
79. Parkinson B, Sermet C, Clement F, Crausaz S, Godman B, Garner S, et al. Disinvestment and value-based purchasing strategies for pharmaceuticals: an international review. Pharmacoeconomics. 2015;33(9):905–24.
80. Simoens S, Picavet E, Dooms M, Cassiman D, Morel T. Cost-effectiveness assessment of orphan drugs: a scientific and political conundrum. Appl Health Econ Health Policy. 2013;11(1):1.
81. Vogler S, Zimmermann N, Ferrario A, Wirtz VJ, de Joncheere K, Pedersen HB, et al. Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. J Pharm Policy Pract. 2016;9(1):1.
82. Russo P, Mennini FS, Siviero PD, Rasi G. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21(10):2081–7.
83. Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N. PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System (PHIS); commissioned by the European Commission and the Austrian Federal Ministry of Health, 2010. http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/PHIS_HospitalPharma_Report.pdf. Accessed 15 Nov 2014.
84. Er S. PHIS Hospital Pharma Report Denmark. Vienna: Pharmaceutical Health Information System (PHIS), 2009.
85. Festöy H, Ognøy AH. PPRI pharma profile Norway. Vienna: Pharmaceutical Pricing and Reimbursement Information (PPRI); 2015.
86. Leopold C, Habl C, Vogler S. Tendering of Pharmaceuticals in EU Member States and EEA countries. Results from the country survey. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2008.
87. Dylst P, Vulto A, Simoens S. Tendering for outpatient prescription pharmaceuticals: what can be learned from current practices in Europe? Health Policy. 2011;101(2):146–52.
88. Gombocz M, Vogler S, Zimmermann N. Ausschreibungen für Arzneimittel: Erfahrungen aus anderen Ländern und Umsetzungsstrategien für Österreich [Tendering for Medicines: Experiences from other countries and implementation strategies for Austria]. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH; 2016.
89. Kanavos P. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands and Germany. London: EMINET, January. 2012. Available at: http://www.progenerika.de/wp-content/uploads/2013/02/Anlage-2_Tendering-Report-EMINET-13OCT2012-FINAL.pdf. Accessed 30 Apr 2016.
90. Kanavos P, Seeley L, Vandoros S. Tender systems for outpatient pharmaceuticals in the European Union: Evidence from the Netherlands, Germany and Belgium. London: European Medicines Information Network (EMINet); 2009.
91. Carradinha H. Tendering short-term pricing policies and the impact on patients, governments and the sustainability of the generic medicines industry. J Generic Med Bus J Generic Med Sect. 2009;6(4):351–61.
92. VanHaeren E, Arickx F, Soete E, Bormans V, Mortier M, Leveque F. PCV162 Public tendering for off patent medicines in Belgium—the simvastatin case. Value Health. 2009;12(7):A343.
93. Vogler S. The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries—an overview. Generics Biosimilars Initiat (GaBI) J. 2012;1(2):93–100.
94. Dylst P, Vulto A, Simoens S. Demand-side policies to encourage the use of generic medicines: an overview. Expert Rev Pharmacoecon Outcomes Res. 2013;13(1):59–72.
95. Vogler S, Schneider P, Gombocz M. Maßnahmen der Generikaförderung in Europa [Measures to enhance generics uptake in Europe]. Vienna: Gesundheit Österreich Forschungs- und Planungs GmbH; 2016.
96. Vogler S. How large are the differences between originator and generic prices? Analysis of five molecules in 16 European countries. Farmeconomia Health Econ Ther Pathw. 2012;13(Suppl 3):29–41.
97. Vogler S, Leopold C. Access to essential medicines in Portugal. Vienna: ÖBIG Forschungs- und Planungsgesellschaft mbH; 2009.
98. Gouya G, Reichardt B, Bidner A, Weissenfels R, Wolzt M. Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurances and patients [Article in German]. Wien Klin Wochenschr. 2008;120(3–4):89–95.
99. Vogler S, Zimmermann N, et al. Policy interventions related to medicines: survey of measures taken in European countries during 2010–2015. Health Policy. 2016;120(12):1363–77.
100. Danzon PM, Furukawa MF. Prices and availability of pharmaceuticals: evidence from nine countries. Health Affairs. 2003:W3–521. doi:10.1377/hlthaff.w3.521.
101. Godman B, Bennie M, Baumgärtel C, Sović-Brkičić L, Burkhardt T, Fürst J, et al. Essential to increase the use of generics in Europe to maintain comprehensive health care? Farmeconomia Health Econ Ther Pathw. 2012;13(3S):5–20.
102. Dylst P, Vulto A, Godman B, Simoens S. Generic medicines: solutions for a sustainable drug market? Appl Health Econ Health Policy. 2013;11(5):1–7.
103. Sermet C, Andrieu V, Godman B, Van Ganse E, Haycox A, Reynier JP. Ongoing pharmaceutical reforms in France: implications for key stakeholder groups. Appl Health Econ Health Policy. 2010;8(1):7–24.
104. European Commission Competition Directorate-General. Pharmaceutical sector inquiry. Brussels: European Commission; 2009.
105. Simoens S. Generic and biosimilar medicines: quid? Farmeconomia Health Econom Ther Pathw. 2012;13(3S):3–4.
106. Dylst P, Vulto A, Simoens S. Overcoming challenges in market access of generic medicines in the European Union. J Generic Med Bus J Generic Med Sect. 2012;9(1):21–8.
107. Heinze G, Hronsky M, Reichardt B, Baumgärtel C, Müllner M, Bucsics A, et al. Potential savings in prescription drug costs for hypertension, hyperlipidemia, and diabetes mellitus by equivalent drug substitution in Austria: a nationwide cohort study. Appl Health Econ Health Policy. 2014;13(2):1–13.
108. Simoens S, De Coster S. Sustaining generic medicines markets in Europe. J Generic Med. 2006;3(4):268.
109. Cameron A, Mantel-Teeuwisse AK, Leufkens HGM, Laing RO. Switching from originator brand medicines to generic equivalents in selected developing countries: how much could be saved? Value Health. 2012;15(5):664–73.
110. Ubeda A, Cardo E, Sellés N, Broseta R, Trillo JL, Fernández-Llimós F. Antidepressant utilization in primary care in a Spanish region. Soc Psychiatry Psychiatr Epidemiol. 2007;42(3):181–8.
111. European Medicines Agency (EMA). European public assessment reports London 2106. http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 7 July 2016.
112. Schellekens H, Smolen JS, Dicato M, Rifkin RM. Safety and efficacy of biosimilars in oncology. Lancet Oncol. 2016;17(11):e502–9.
113. Food and Drug Adminstration (FDA). FDA approves Inflectra, a biosimilar to Remicade. Press release. 2016. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm494227.htm. Accessed 6 July 2016.
114. European Commission. Multi-stakeholder Workshop on Biosimilar Medicinal Products. Summary. 20 June 2016. http://ec.europa.eu/DocsRoom/documents/19302/attachments/1/translations/en/renditions/native. Accessed 3 Nov 2016.
115. Goll GL, Olsen IC, Jorgensen KK, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Biosimilar Infliximab (CT-P13) Is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. Arthritis Rheumatol. 2016;968(suppl. 10). http://acrabstracts.org/abstract/biosimilar-infliximab-ct-p13-is-not-inferior-to-originator-infliximab-results-from-a-52-week-randomized-switch-trial-in-norway/. Accessed 3 Nov 2016.
116. Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: how can payers get long-term savings? PharmacoEconomics. 2016;34(6):609–16.
117. Vogler S, Peter S, Gombocz M, Zimmermann N. Differences in pricing policies for generic and biosimilar medicines. Value Health. 2016;19(7):A350.
118. European Biopharmaceutical Enterprises. What pricing and reimbursement policies to use for off-patent biologicals?—results from the EBE 2014 biological medicines policy survey. Generics Biosimilars Initiat J (GaBI Journal). 2015;4(1):17–24.
119. Renwick MJ, Smolina K, Gladstone EJ, Weymann D, Morgan SG. Postmarket policy considerations for biosimilar oncology drugs. Lancet Oncol. 2016;17(1):e31–8.
120. Vogler S, Zimmermann N, Leopold C, Habl C, Mazag J. Discounts and rebates granted for medicines for hospital use in five European countries. Open Pharmacoecon Health Econ J. 2013;5:1–10.
121. GaBI Online. Huge discount on biosimilar infliximab in Norway. Generics Biosimilars Initiat J (GaBI Journal). 2015. http://www.gabionline.net/Biosimilars/General/Huge-discount-on-biosimilar-infliximab-in-Norway. Accessed 3 Nov 2016.
122. Council of the European Union. Council conclusions on strengthening the balance in the pharmaceutical systems in the EU and its Member States. 17 June 2016. http://www.consilium.europa.eu/press-releases-pdf/2016/6/47244642812_en.pdf. Accessed 3 July 2016.
123. European Commission. Medical Countermeasures that could be procured in common under the joint procurement agreement. http://ec.europa.eu/health/preparedness_response/docs/jpa_note_scope_en.pdf. Accessed 3 June 2016. Luxembourg: 2014.
124. Ministre des Affaires sociales et de la Santé publique. The Grand Duchy of Luxemburg Joins Belgium-Netherlands Initiative on Orphan Drugs, Communiqué de presse 24 September 2015 2016 [3 June 2016]. http://www.deblock.belgium.be/fr/grand-duchy-luxemburg-joins-belgium-netherlands-initiative-orphan-drugs. Accessed 3 June 2016.
125. Bundesministerium für Gesundheit [Federal Ministry of Health]. Oberhauser: Österreich tritt Benelux-Kooperation für Arzneimittelpolitik bei [Oberhauser: Austria joins the Benelux cooperation on pharmaceutical policy]. 17 June 2016. http://www.bmgf.gv.at/home/Startseite/aktuelle_Meldungen/Oberhauser_Oesterreich_tritt_Benelux_Kooperation_fuer_Arzneimittelpolitik_bei. Accessed 4 July 2016.
126. Kristensen FB, Mäkelä M, Neikter SA, Rehnqvist N, Håheim LL, Mørland B, et al. European network for Health Technology Assessment, EUnetHTA: planning, development, and implementation of a sustainable European network for Health Technology Assessment. Int J Technol Assess Health Care. 2009;25(S2):107–16.
127. European Medicines Agency (EMA). Early dialogue between regulators and health technology assessment bodies key to medicines development. EMA and multiple stakeholders to develop tools for industry. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/11/news_detail_001979.jsp&mid=WC0b01ac058004d5c1. Accessed 28 June 2016. [press release]. 28 Nov 2013.
128. European Medicines Agency (EMA). Pilot project on adaptive licensing. London: 19 March 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Other/2014/03/WC500163409.pdf. Accessed 3 June 2016.
129. National Institute for Health and Care Excellence (NICE). Public involvement. London. 2016. https://www.nice.org.uk/about/nice-communities/public-involvement. Accessed 6 June 2016.
130. van Thiel G, Stolk P. Background Paper 8.5 Patient and Citizen Involvement. In: World Health Organization, editor. Priority Medicines for Europe and the World 2013 Update. Geneva; 2013.
131. Scottish Medicines Consortium. Capturing the patient and carer voice. Glasgow 2016. https://www.scottishmedicines.org.uk/Public_Involvement/Public_Involvement. Accessed 6 June 2016.
132. European Commission. Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems. http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en:HTML. Accessed 4 Nov 2016.
133. EFPIA. EFPIA Position Paper: Principles for application of international reference pricing systems. 16 July 2014.
134. Review of Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the pricing of medicinal products for human use and their inclusion in the scope of national health insurance systems (Transparency Directive). Joint Position Paper. Submitted by European Social Insurance Platform (ESIP)/Association Internationale de la Mutualité (AIM) on 10 February 2011 [press release]. 2011.
135. Robertson J, Walkom EJ, Henry DA. Transparency in pricing arrangements for medicines listed on the Australian Pharmaceutical Benefits Scheme. Aust Health Rev. 2009;33(2):192–9.
136. Joppi R, Demattè L, Menti AM, Pase D, Poggiani C, Mezzalira L. The Italian horizon scanning project. Eur J Clin Pharmacol. 2009;65(8):775–81.
137. Packer C, Fung M, Stevens A. Analyzing 10 years of early awareness and alert activity in the United Kingdom. Int J Technol Assess Health Care. 2012;28(03):308–14.
138. Godman B, Paterson K, Malmström RE, Selke G, Fagot J-P, Mrak J. Improving the managed entry of new medicines: sharing experiences across Europe. Expert Rev Pharmacoecon Outcomes Res. 2012;12(4):439–41.
139. Nordic Contact Point for Priorization. Memo—Overview of Nordic collaboration within the prioritization area [27 July 2016]. https://nyemetoder.no/Documents/Nordiskkontaktpunkt/Memo-OverviewofNordiccollaboration.pdf. Accessed 27 July 2016.
140. Avorn J. The $2.6 billion pill—methodologic and policy considerations. N Engl J Med. 2015;372(20):1877–9.
141. Sullivan T. New York Introduces Pharmaceutical Cost Transparency Bill: Policy and Medicines; 18 May 2016. http://www.policymed.com/2015/05/new-york-introduces-pharmaceutical-cost-transparency-bill.html. Accessed 7 July 2016.
142. World Health Organization. Global strategy and plan of action on public health, innovation and intellectual property. Geneva: World Health Organization; 2011.
143. Velásquez G, Seuba X. Rethinking global health: a binding convention for R&D for pharmaceutical products. South Center Res Pap. 2011;42:29.
144. Jayadev A, Stiglitz J. Two ideas to increase innovation and reduce pharmaceutical costs and prices. Health Aff. 2009;28(1):w165–8.
145. Moon S, Bermudez J, t Hoen E. Innovation and access to medicines for neglected populations: could a treaty address a broken pharmaceutical R&D system? PLoS Med. 2012;9(5):e1001218.
146. Røttingen J-A, Chamas C. A new deal for global health R&D? The recommendations of the consultative expert working group on research and development (CEWG). PLoS Med. 2012;9(5):e1001219.
147. Love J, Hubbard T. Bid Idea: prizes to Stimulate R&D for New Medicines. Chi-Kent L Rev. 2007;82:1519.
148. Balasegaram M, Bréchot C, Farrar J, Heymann D, Ganguly N, Khor M, et al. A global biomedical R&D fund and mechanism for innovations of public health importance. PLoS Med. 2015;12(5):e1001831.
149. The Review on Antimicrobial Resistance. Tackling drug-resistent infections globally: final report and recommendations. London: Wellcome Trust and UK Government; 2016.
150. United Nations Secretary General’s High-Level Panel on Access to Medicines. Report of the United Nations Secretary General’s High-Level Panel on Access to Medicines. Promoting innovation and access to health technologies. September 2016.
151. Wirtz VJ, Hogerzeil HV, Gray AL, Bigdeli M, de Joncheere CP, Ewen MA, et al. Essential medicines for universal health coverage. Lancet. 2016. doi:10.1016/S0140-6736(16)31599-9.
152. Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al. Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. Eur J Clin Pharmacol. 2013;69(1):73–8.
153. Leopold C. Pharmaceutical policy analysis—a European perspective on pricing and reimbursement in challenging times. Utrecht: Utrecht University; 2014.
154. Almarsdóttir AB, Traulsen JM. Studying and evaluating pharmaceutical policy—becoming a part of the policy and consultative process. Pharm World Sci. 2006;28(1):6–12.
155. Gotham D, Onarheim KH, Barber MJ. How the MDGs gave up on measuring access to medicines. Lancet Glob Health. 2016;4(5):e296–7.
156. Kaplan WA, Ritz LS, Vitello M, Wirtz VJ. Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010. Health Policy. 2012;106(3):211–24.